(Q28287175)

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Recent clinical progress in Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

METABOLISM OF GLUCOCEREBROSIDES. II. EVIDENCE OF AN ENZYMATIC DEFICIENCY IN GAUCHER'S DISEASE.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

The Gaucher registry: demographics and disease characteristics of 1698 patients with Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

The clinical and demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Gynecologic and obstetric aspects of Gaucher's disease: a survey of 53 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Pulmonary hypertension in type 1 Gaucher's disease: genetic and epigenetic determinants of phenotype and response to therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Enzyme therapy for Gaucher disease: the first 5 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Guidance on the use of miglustat for treating patients with type 1 Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

The uptake of native and desialylated glucocerebrosidase by rat hepatocytes and Kupffer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Modifying exogenous glucocerebrosidase for effective replacement therapy in Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

The long-term international safety experience of imiglucerase therapy for Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Recombinant therapeutic proteins: production platforms and challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Decreased bone density in splenectomized Gaucher patients receiving enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Bisphosphonate treatment of osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Osteoporosis and determinants of bone density in patients with Crohn's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Evidence-based recommendations for monitoring bone disease and the response to enzyme replacement therapy in Gaucher patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Individualization of long-term enzyme replacement therapy for Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Pregnancy after avascular necrosis of the femur complicating Gaucher's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Pregnancies in Gaucher disease: a 5-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Anesthesia for obstetric patients with Gaucher disease: survey and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Convection perfusion of glucocerebrosidase for neuronopathic Gaucher's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Neuronopathic forms of Gaucher's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Management of neuronopathic Gaucher disease: a European consensus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Lysosomal storage diseases: natural history and ethical and economic aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

A less costly regimen of alglucerase to treat Gaucher's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

The outcome of clinical parameters in adults with severe Type I Gaucher disease using very low dose enzyme replacement therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Therapeutic goals in the treatment of Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Withdrawal of enzyme replacement therapy in Gaucher's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Clinical consequences of interrupting enzyme replacement therapy in children with type 1 Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Oral maintenance clinical trial with miglustat for type I Gaucher disease: switch from or combination with intravenous enzyme replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Outcome of ten years' echocardiographic follow-up in children with Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Orthopedic considerations in Gaucher disease since the advent of enzyme replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987

The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.9.11.1987